Items Tagged ‘PARP inhibitor’

October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


July 13th, 2016

Niraparib Improves Progression-Free Survival in Ovarian Cancer

By

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer, and is the fifth most common cause of cancer-related deaths among women. Since there are no generalized […]

View full entry

Tags: BRCA1, BRCA2, News, niraparib, NOVA trial, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer


September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


June 15th, 2015

Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer

By

The drug rucaparib appears active in women with recurrent BRCA-positive ovarian cancer that has progressed after previous treatment. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women […]

View full entry

Tags: BCRA-positive ovarian cancer, News, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib


May 26th, 2015

Lynparza™

By

Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

View full entry

Tags: Biological Therapy, Drug Dictionary, L, Ovarian Cancer, PARP inhibitor


May 26th, 2015

Olaparib

By

Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

View full entry

Tags: Biological Therapy, Drug Dictionary, lynparza, O, Ovarian Cancer, PARP inhibitor